Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11322)	10/19/2017 3:30:17 PM
From: scaram(o)uche	Respond to of 12215

.......Chief, Dermatology, Philadelphia V.A. Hospital, Professor of Dermatology at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, Professor of Medicine, University of Pennsylvania and Principal Investigator in the Phase 2 study...... Wow. Yeah, n=22. But I want it to be real, soooooooo bad.

To: tuck who wrote (11322)	10/25/2017 1:34:39 PM
From: scaram(o)uche	Respond to of 12215

No respect, trading under the offering price. (Oooops, there it went.... well, close to offering price.) I am again a shareholder. Looks like they're going to be chronic on secondaries, so probably no hurry. Let's frame this clearly, given the jackass twit sniping.... there is NO doubt that tickling CB2 is inhibitory in a myriad of inflammation models. If this early data is actually reflecting eventual trial success? Whompers. So, tril and crbp... recent low patient number "what if" data. A single patient for tril. ;-) Add incy deal and mgnx's LAG-3/PD-1 maybe gets a psychological leg up. HUGE market potentials.